Managers / Q4 2020 · view latest →
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
CIK 0001047859 · 500 CRESCENT COURT, SUITE 260, DALLAS, TX, 75201 · 2148713700
Summary
Paragon Associates & Paragon Associates II Joint Venture reported $65M in U.S.-listed holdings across 10 positions for Q4 2020.
The portfolio is heavily concentrated: Reata Pharmaceuticals alone accounts for 26.6% of reported value.
Compared with Q3 2020, the fund opened 4 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 94.3% · $61M
- ETP · 5.7% · $4M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BNYBANK NEW YORK MELLON CORP | NEW | +100.0K | 100.0K | +$4M | $4M |
| VERSO CORP | NEW | +147.3K | 147.3K | +$2M | $2M |
| WFCWELLS FARGO CO NEW | NEW | +25.0K | 25.0K | +$755,000 | $755,000 |
| ATNIATN INTL INC | NEW | +9.0K | 9.0K | +$376,000 | $376,000 |
| ABXBARRICK GOLD CORPORATION | SOLD OUT | −300.0K | 0 | −$8M | $0 |
| COMMUNITY BANKERS TR CORP | SOLD OUT | −193.6K | 0 | −$983,000 | $0 |
| SPYSPDR S&P 500 ETF TR | TRIMMED | −40.0K | 10.0K | −$13M | $4M |
| NVGSNAVIGATOR HOLDINGS LTD | TRIMMED | −140.0K | 1.23M | +$2M | $13M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | REATA PHARMACEUTICALS INC | CL A | 26.61% | $17M | 140.0K |
| 2 | NEMNEWMONT CORPhistory → | COM | 23.03% | $15M | 250.0K |
| 3 | NVGSNAVIGATOR HOLDINGS LTDhistory → | SHS | 20.63% | $13M | 1.23M |
| 4 | EPSNEPSILON ENERGY LTDhistory → | COM | 7.90% | $5M | 1.38M |
| 5 | BNYBANK NEW YORK MELLON CORPhistory → | COM | 6.53% | $4M | 100.0K |
| 6 | SPYSPDR S&P 500 ETF TRhistory → | TR UNIT | 5.75% | $4M | 10.0K |
| 7 | IRIXIRIDEX CORPhistory → | COM | 5.09% | $3M | 1.32M |
| 8 | VERSO CORP | CL A | 2.72% | $2M | 147.3K |
| 9 | WFCWELLS FARGO CO NEWhistory → | COM | 1.16% | $755,000 | 25.0K |
| 10 | ATNIATN INTL INC | COM | 0.58% | $376,000 | 9.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $74M | 14 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $48M | 12 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $56M | 12 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $63M | 15 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $43M | 13 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $43M | 12 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $56M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $41M | 11 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $56M | 16 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $44M | 15 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $31M | 10 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $49M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 11 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $54M | 17 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $50M | 12 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 11 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $54M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $63M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $88M | 17 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $75M | 16 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $66M | 11 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $65M | 10 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $91M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 13 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $178M | 19 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $130M | 21 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $130M | 25 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 30 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $75M | 21 | Feb 13, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.